The 10 analysts offering 12-month price forecasts for Reata Pharmaceuticals Inc have a median target of 57.00, with a high estimate of 115.00 and a low estimate of 35.00. The median estimate represents a +45.45% increase from the last price of 39.19.
The current consensus among 10 polled investment analysts is to Buy stock in Reata Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.19
Reporting Date Mar 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.